• Genetic Immunity Press Releases

    To access our corporate press release archive please first select the year and then browse news items by month. Press releases are available as PDF files.

    Forward-looking statements

    These press releases may contain "forward-looking statements" for the purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's current expectations about its future plans and performance, including statements concerning the impact of marketing strategies, new product introductions and innovation, deliveries of product, sales, earnings, and margins. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to Power of the Dream Ventures's most recent Form 10-K and subsequent filings for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in these press releases in order to reflect events or circumstances after the date of these releases.

    To view or print PDF files please download the free Adobe Acrobat Reader.


Sep 28 - Power of the Dream Ventures acquires Genetic Immunity. [ PDF ]


Oct 8 - Genetic Immunity receives GMP certification for in-house manufacturing facility. [ PDF ]
Oct 12 - DKFZ and Genetic Immunity Sign Collaboration Agreement to Develop HPV Therapeutic Vaccine. [ PDF ]
Oct 17 - Genetic Immunity Successfully Completes ISO audit. [ PDF ]


Mar 29 - Power of the Dream Ventures Announces Dr. Julianna Lisziewicz presentation at Innovation in Health, Brussels. [ PDF ]


Apr 4 - Power of the Dream Ventures Announces Genetic Immunity signs West Nile Virus vaccine development agreement. [ PDF ]
Apr 11 - Power of the Dream Ventures. Genetic Immunity announces positive Phase II data for HIV vaccine – results show median 70% percent viral load reduction. [ PDF ]


Feb 23 - Power of the Dream Ventures signs business development agreement with Genetic Immunity. [ PDF ]
Feb 26 - Genetic Immunity, Retrospective - Next generation DNA vaccine - DermaVir nanomedicine for the treatment of HIV-AIDS. [ PDF ]


Mar 4 - Genetic Immunity, Retrospective - Phase 1 trial results for the Company's HIV vaccine candidate lead product. [ PDF ]
Mar 11 - Genetic Immunity, InPlay - Genetic Immunity receives CE marking for DermaPrep, a unique transdermal drug delivery device. [ PDF ]
Mar 19 - Genetic Immunity, InPlay - ACTG completes Phase I-II, Randomized, Double-Blind Study to evaluate the Safety, Tolerability, and Immunogenicity of DermaVir Vaccine. [ PDF ]


Apr 1 - Genetic Immunity, InPlay - Genetic Immunity licenses plasmid DNA purification technology. [ PDF ]
Apr 16 - Genetic Immunity, InPlay - Second Phase II clinical trial commences in Italy on Company’s lead product candidate DermaVir Patch HIV vaccine. [ PDF ]
Apr 23 - Genetic Immunity, InPlay - Company to attend CLINAM European Conference for Clinical Nanomedicine. [ PDF ]


May 13 - Genetic Immunity, InPlay - Company to present at the Bio International Convention in Atlanta. [ PDF ]


Jun 11 - Genetic Immunity, InPlay - Company completes patient enrollment in German Phase II trial of HIV immune therapy vaccine lead product candidate. [ PDF ]
Jun 18 - Genetic Immunity, InPlay - Company to present at Phacilitate’s 8th annual European Vaccine Forum. [ PDF ]


Jul 1 - Genetic Immunity, InPlay - Company successfully completes patient enrollment in Italian Phase II trial of DermaVir Patch HIV topical immunotherapeutic nanomedicine. [ PDF ]